26/08/2024
Cbl-b protein is a type of E3 ubiquitin ligase that negatively regulates immune function and shows great potential as a novel intracellular immune checkpoint drug target.
ReadCrystal Biotechnology has successfully expressed, purified, and crystallized the 38-427 fragment of the Cbl-b protein, which includes the TKB, LHR, and RING domains. We have also accumulated extensive data on the co-crystal structures of this target and its inhibitors. In addition, we have experience with proteins related to the Cbl-b pathway, both upstream and downstream, which allows us to shorten turnaround time to 1-2 months.
For more information on the gallery structure of ReadCrystal, please stay tuned! Discover more: https://www.linkedin.com/pulse/gallery-structurecbl-b-readcrystal-technology-enddc/?trackingId=ltAzS1xzQPaJHwnnpMhsQg%3D%3D
Cbl-b protein is a type of E3 ubiquitin ligase that negatively regulates immune function and shows great potential as a novel intracellular immune checkpoint drug target. ReadCrystal Biotechnology has completed the expression and structural analysis of the Cbl-b target protein.